Pentostatin
| Clinical data | |
|---|---|
| Trade names | Nipent |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a692004 |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | n/a |
| Protein binding | 4% |
| Metabolism | Hepatic, minor |
| Elimination half-life | 2.6 to 16 hours, mean 5.7 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.164.991 |
| Chemical and physical data | |
| Formula | C11H16N4O4 |
| Molar mass | 268.273 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Pentostatin (or 2′-deoxycoformycin, trade name Nipent, manufactured by SuperGen) is an anticancer chemotherapeutic drug.